The role of CREB and BDNF in neurobiology and treatment of Alzheimer's disease

M Amidfar, J de Oliveira, E Kucharska, J Budni, YK Kim - Life sciences, 2020 - Elsevier
Alzheimer's disease (AD) is the most common form of dementia worldwide. β-amyloid
peptide (Aβ) is currently assumed to be the main cause of synaptic dysfunction and cognitive …

Beyond the hippocampus and the SVZ: adult neurogenesis throughout the brain

MP Jurkowski, L Bettio, E K. Woo, A Patten… - Frontiers in cellular …, 2020 - frontiersin.org
Convincing evidence has repeatedly shown that new neurons are produced in the
mammalian brain into adulthood. Adult neurogenesis has been best described in the …

Brain-derived neurotrophic factor in neurodegenerative diseases

C Zuccato, E Cattaneo - Nature Reviews Neurology, 2009 - nature.com
Abstract Changes in the levels and activities of neurotrophic factors, such as brain-derived
neurotrophic factor (BDNF), have been described in a number of neurodegenerative …

Molecular mechanisms and potential therapeutical targets in Huntington's disease

C Zuccato, M Valenza, E Cattaneo - Physiological reviews, 2010 - journals.physiology.org
Huntington's disease (HD) is a neurodegenerative disorder caused by a CAG repeat
expansion in the gene encoding for huntingtin protein. A lot has been learned about this …

Targeting protein kinases in central nervous system disorders

LK Chico, LJ Van Eldik, DM Watterson - Nature reviews Drug discovery, 2009 - nature.com
Protein kinases are a growing drug target class in disorders in peripheral tissues, but the
development of kinase-targeted therapies for central nervous system (CNS) diseases …

Human mesenchymal stem cells genetically engineered to overexpress brain-derived neurotrophic factor improve outcomes in Huntington's disease mouse models

K Pollock, H Dahlenburg, H Nelson, KD Fink, W Cary… - Molecular Therapy, 2016 - cell.com
Huntington's disease (HD) is a fatal degenerative autosomal dominant neuropsychiatric
disease that causes neuronal death and is characterized by progressive striatal and then …

Huntington's disease: the current state of research with peripheral tissues

J Sassone, C Colciago, G Cislaghi, V Silani… - Experimental …, 2009 - Elsevier
Huntington's disease (HD) is a genetically dominant condition caused by expanded CAG
repeats. These repeats code for a glutamine tract in the HD gene product huntingtin (htt) …

Brain-derived neurotrophic factor in patients with Huntington's disease

C Zuccato, M Marullo, B Vitali, A Tarditi, C Mariotti… - PLoS …, 2011 - journals.plos.org
Reduced Brain-Derived Neurotrophic Factor (BDNF) levels have been described in a
number of patho-physiological conditions, most notably, in Huntington's disease (HD), a …

Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease

SJ McConoughey, M Basso… - EMBO molecular …, 2010 - embopress.org
Caused by a polyglutamine expansion in the huntingtin protein, Huntington's disease leads
to striatal degeneration via the transcriptional dysregulation of a number of genes, including …

Methylene blue modulates huntingtin aggregation intermediates and is protective in Huntington's disease models

EM Sontag, GP Lotz, N Agrawal, A Tran… - Journal of …, 2012 - Soc Neuroscience
Huntington's disease (HD) is a devastating neurodegenerative disorder with no disease-
modifying treatments available. The disease is caused by expansion of a CAG trinucleotide …